BSE filing, NSE: AUROLAB. Summary written from the filing by ALFA Finder's alert engine.
Auro Laboratories Ltd: key numbers
- Share price
- ₹232.75
- Market cap
- ₹145.1 Cr
- Revenue (annual)
- ₹32.61 Cr
- Net profit (annual)
- ₹3.53 Cr
- P/E (TTM)
- 31.0×Sector 45.9×
- Promoter holding
- 52.40%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Auro Laboratories Ltd
All →Auro Laboratories Other Announcement
Auro Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Auro Laboratories Q1 FY27 Results: Turns Profitable, Net Profit ₹1 Cr
Auro Laboratories Ltd reported revenue from operations of ₹8.8 Cr (+214.3% YoY) and net profit of ₹1 Cr for Q1 FY27.
- Key figure
- Net profit ₹1 Cr
Auro Laboratories Annual General Meeting
Auro Laboratories Limited held its 37th Annual General Meeting on August 11, 2026, via video conferencing. The company conducted all items of business as listed in the notice.
Auro Laboratories Board Meeting Date
Auro Laboratories Ltd has scheduled a board meeting on August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Auro Laboratories Other Announcement
Auro Laboratories issued a notice to shareholders regarding its 37th AGM scheduled for August 11, 2026. The letter provides web-links to access the FY 2025-26 Annual Report.
Auro Laboratories Annual General Meeting
Auro Laboratories has scheduled its 37th Annual General Meeting for August 11, 2026. Agenda includes adopting financial statements and re-appointing Mr. Kiran Kulkarni as Whole-Time Director.
Other regulatory approval announcements
All →Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.